Scholarlink

<p>The lysyl oxidase family is a group of copper-containing amine oxidases involved in the remodeling of the extracellular matrix, and regulates cell signaling, metabolism, organ development, and immunity by modifying the cellular matrix. Among them, LOXL3 had been shown to regulate the proliferation, migration, and invasion of breast, colorectal, lung, melanoma, and gastric cancers. Differential expression of LOXL3 in tumor affects tumor progression by modulating immune microenvironment, where LOXL3 plays a role in regulating immune cell infiltration, immune checkpoints, and the establishment of tumor drug resistance. Here, we summarize the structure, mechanism, and functional role of LOXL3 in tumor and tumor immune microenvironment. Further, we explored strategies to improve the immunotherapy efficacy by targeting LOXL3 in tumor. Based on its properties in immunity, we explored strategies to improve the immune efficacy of LOXL3 in immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The "dual personality" of LOXL3: a tumor accomplice and a new hope for immunotherapy

  • 期刊论文

  • 发表日期：

    2025年11月11日

查看全文
  • Shuang Wu,
  • Chao Huang

摘要

The lysyl oxidase family is a group of copper-containing amine oxidases involved in the remodeling of the extracellular matrix, and regulates cell signaling, metabolism, organ development, and immunity by modifying the cellular matrix. Among them, LOXL3 had been shown to regulate the proliferation, migration, and invasion of breast, colorectal, lung, melanoma, and gastric cancers. Differential expression of LOXL3 in tumor affects tumor progression by modulating immune microenvironment, where LOXL3 plays a role in regulating immune cell infiltration, immune checkpoints, and the establishment of tumor drug resistance. Here, we summarize the structure, mechanism, and functional role of LOXL3 in tumor and tumor immune microenvironment. Further, we explored strategies to improve the immunotherapy efficacy by targeting LOXL3 in tumor. Based on its properties in immunity, we explored strategies to improve the immune efficacy of LOXL3 in immunotherapy.